Clinical trial
Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT02478424 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation
- Lead sponsor
- Rabin Medical Center
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- July 31, 2015
- Completion date
- June 30, 2017
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.